Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03584854 · ClinicalTrials.gov registry record · Phase 4
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT03584854 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 100 participants.
The verdict
NCT03584854, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate in a randomized fashion the comparative efficacy of two second-line medications, methylergonovine and carboprost for treating atonic postpartum hemorrhage (PPH). The investigators hypothesize that administration of methylergonovine will produce superior uterine tone to carboprost in atonic PPH.
Interventions
- DRUG 15-methyl prostaglandin F2α
- DRUG Methylergonovine Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2022-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03584854
The ClinicalTrials.gov registry entry for NCT03584854 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 15-methyl prostaglandin F2α is the first listed.
NCT03584854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03584854 about?
NCT03584854 is a clinical study titled "Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial". The aim of this study is to evaluate in a randomized fashion the comparative efficacy of two second-line medications, methylergonovine and carboprost for treating atonic postpartum hemorrhage (PPH). The investigators hypothesize that administration of methylergonovine will produce superior uterine t...
What is the current status of trial NCT03584854?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2019-03-01. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT03584854?
The interventions under investigation include: 15-methyl prostaglandin F2α (DRUG), Methylergonovine Maleate (DRUG).
Who is sponsoring clinical trial NCT03584854?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.